Clinical Research Directory

Inclusion Criteria: * Female aged ≥ 18 and ≤ 75 years. * Premenopausal patients must meet the eligibility of LHRH agonist therapy during the study period. * Histological confirmation of breast cancer with evidence of locally advanced or metastatic disease. Locally advanced diseased is not amenable to surgical resection or radiation therapy with curative intent. * Untreated with any systemic anticancer therapy for their locally advanced or metastatic disease. Patients received prior standard (neo)adjuvant endocrine therapy must meet the following criteria: 1. Complete neoadjuvant or adjuvant endocrine therapy for at least 24 months without recurrence or metastasis during treatment and 12 months after completion of treatment 2. CDK4/6 inhibitor therapy for at least 12 months, if used in the (neo)adjuvant phase, with no recurrence or metastasis during treatment or within 12 months after completion of treatment. * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1. * Measurable disease or non-measurable bone only disease as defined by RECIST version 1.1 * Adequate organ function. Exclusion Criteria: * In visceral crisis at risk of immediately life-threatening complications in the short term. * Inflammatory breast cancer. * Uncontrolled or untreated brain metastasis. * Individuals with a known history of allergy to any component of this medication.